Saturday, June 20, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 70 of 1,261
  1. US 12186324

    Imidazopiperazine inhibitors of transcription activating proteins

    The Board of Regents of the University of Texas System · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted
  2. US 12186330

    Compositions for improving cell viability and methods of use thereof

    Amylyx Pharmaceuticals, Inc. · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted
  3. US 12186282

    Treatment of 22Q11.2 deletion syndrome with cannabidiol

    Harmony Biosciences Management, Inc. · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted
  4. US 12186314

    Compositions and methods for treatment, amelioration, and prevention of anesthesia-induced hypothermia

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted
  5. US 12188039

    Recombinant adeno-associated viral vector for gene delivery

    The Board of Regents of the University of Texas System · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted
  6. US 12187779

    Anti-human papillomavirus 16 E6 T cell receptors

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted
  7. US 12187746

    C26-linked rapamycin analogs as mTOR inhibitors

    Revolution Medicines, Inc. · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted
  8. US 12187754

    LpxC inhibitors and uses thereof

    BLACKSMITH MEDICINES, INC. · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted
  9. US 12186375

    Factor VIII chimeric and hybrid polypeptides, and methods of use thereof

    BIOVERATIV THERAPEUTICS INC. · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted
  10. US 12187772

    IL10 agonists and methods of use thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted
  11. US 12186368

    Compositions and methods for treatment of protease mediated disease

    The Regents of the University of California · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted
  12. US 12187799

    Dual specificity antibodies to PD-L1 and PD-L2 and methods of use therefor

    The Board of Regents of the University of Texas System · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted
  13. US 12186306

    Methods of treatment for cystic fibrosis

    Vertex Pharmaceuticals Incorporated · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted
  14. US 12188020

    Methods for reducing Ataxin-2 expression

    Ionis Pharmaceuticals, Inc. · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted
  15. US 12186313

    Pyridazinone compounds and their use as DAAO inhibitors

    Takeda Pharmaceutical Company Limited · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted
  16. US 12186363

    Compositions and methods for dengue virus chimeric constructions in vaccines

    The Government of the United States of America as represented by the Secretary of the Deptartment of Health and Human Services · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted
  17. US 12187731

    Compounds useful as inhibitors of ATR kinase

    Vertex Pharmaceuticals Incorporated · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted
  18. US 12186384

    Compositions and methods for making and using thermostable immunogenic formulations with increased compatibility of use as vaccines against one or more pathogens

    The Regents of the University of Colorado, a Body Corporate · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted
  19. US 12187777

    Engineered invariant natural killer T (iNKT) cells and methods of making and using thereof

    The Regents of the University of California · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted
  20. US 12187780

    Car t-cells comprising inactivated CBL and CBL-B genes

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted
  21. US 12187698

    Crystalline forms of C21H22Cl2N4O2

    Vertex Pharmaceuticals Incorporated · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted
  22. US 12187694

    SLC26A3 inhibitors and use thereof

    The Regents of the University of California · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted
  23. US 12187679

    Hydroxylated psilocybin derivatives and methods of using

    Enveric Biosciences Canada Inc. · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted
  24. US 12186428

    Combination taxoid nanoemulsion with immunotherapy in cancer

    Northwestern University · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.